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1. Introduction
Nuchal translucency (NT) is the assessment of the amount of fluid behind the neck of the fetus,
also known as the nuchal fold. An anechoic space is visible and measurable sonographically in
all fetuses between the 11th and the 14th week of the pregnancy (Figure 1). Underlying patho‐
physiological mechanisms for nuchal fluid collection under the skin include cardiac dysfunc‐
tion, venous congestion in the head and neck, altered composition of the extracellular matrix,
failure of lymphatic drainage, fetal anemia or hypoproteinemia and congenital infection [1].
The abnormal accumulation of nuchal fluid decreases after the 14th week.
Figure 1. Normal nuchal translucency thickness (NT)
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1.1. Increased NT in chromosomally abnormal fetuses
The association between the increased NT and the chromosomal abnormalities has been
well documented (Figure 2). It helps us identify the high-risk fetuses for trisomy 21 and oth‐
er chromosomal abnormalities [2,3].
Figure 2. Increased nuchal translucency thickness (NT)
The findings of numerous studies suggest that an effective first trimester screening for triso‐
my 21 can be obtained by the combination of maternal age and measurement of fetal NT
[4-11]. At a risk cut-off of 1 in100, the detection rate of trisomy 21 is about 75%, at a false
positive rate of about 2%. The detection rate can be improved to 85% by the additional as‐
sessment of the fetal nasal bone and even more by the Doppler assessment of blood flow
across the tricuspid valve or blood flow in the ductus venosus, which has increased the de‐
tection rate to about 95% at a false positive rate of 2.5% [11].
Our retrospective study of the first trimester screening for trisomy 21 in 5-year period from
2005 to 2010 by employing the combination of maternal age, sonographic measurement of
the fetal NT thickness and assessment of the fetal nasal bone, included 13,049 pregnant
women [12]. The sample represented an unselected population of women with singleton
pregnancies. The cut-off risk for trisomy 21 was set at 1 in 300. The distribution of maternal
age of the examined women was compared to the age distribution in the pregnant popula‐
tion in Slovenia for the same time interval (2005-2010). The balance between the false posi‐
tive rate and the detection rate was studied and the trends were inspected graphically. The
cut-off risk that would yield 5% false positives was calculated for trisomy 21. The average
gestation was 12 4/7 weeks (range from 11 1/7 weeks to 14 0/7 weeks). The average fetal CRL
was 63.2 mm (from 45 mm to 83 mm). The average NT thickness was 1.7 mm (range from
0.9 mm to 13.4 mm). The NT was above the 95th centile of the normal range for the CRL in
75% (15 out of 20) of trisomy 21 pregnancies and in 64% (16 out of 25) pregnancies with oth‐
er chromosomal abnormalities. At the time of the testing the estimated risk for trisomy 21
was 1 in 300 or higher in 3% of all the pregnancies (394 out of 13,049), considering the calcu‐
lation based on FMF program. Three hundred and sixty cases (2.8%) turned out to be false
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positive. At the invasive testing, chromosomal abnormalities were identified in 8.6% of high
risk cases (34 out of 394), which represented one case of fetal chromosomal abnormality, de‐
tected per 12 invasive diagnostic procedures. Consequently we believe that the effective
screening for trisomy 21 can be achieved in the first trimester of pregnancy by the combina‐
tion of maternal age, sonographic measurement of the fetal NT thickness and assessment of
the fetal nasal bone, with detection rate of 85% at a false positive rate of less than 3%.
Karyotype n
Trisomy 21 20
Trisomy 18 10
Trisomy 13 2
45,X (Turner syndrom) 3
47,XXY 2
Mosaic structure 3
Unbalanced structural rearrangements 5
Total 45
Table 1. Chromosomal abnormalities in fetuses and newborns in our sample of 13,049 women with singleton
pregnancies [12].
1.2. Increased NT in chromosomally normal fetuses
The NT can be increased also in chromosomally normal fetuses. When the karyotype is nor‐
mal, the fetus is still at a significant risk of adverse pregnancy outcome e.g. fetal loss, struc‐
tural abnormalities, particularly cardiac defects, various genetic syndromes and delayed
neurodevelopment [9,13]. The prevalence of fetal abnormalities and adverse pregnancy out‐
comes increases with the thickness of NT.
The impact of the increased nuchal fluid collection, seen during the ultrasound examination,
raises the parents’ great anxiety about future fetal development [13]. The risks of adverse
pregnancy outcomes have to be discussed with the parents and an objective counseling has
to be offered to them together with detailed ultrasound examinations later in the pregnancy.
But even in the absence of clear fetal abnormalities, some couples request pregnancy termi‐
nation in such circumstances [14].
Therefore, the aim of this study was to evaluate the pregnancy outcomes of fetuses with in‐
creased NT thickness and normal karyotype in an unselected pregnant population.
2. Subjects and methods
2.1. Study design
The retrospective study included unselected population of pregnant women of Caucasian
ethnic origin appointed for the first trimester ultrasound screening examination at a single
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outpatient clinic between January 4, 2005 and April 30, 2010. Included in the study popula‐
tion were only singleton pregnancies with live fetus from the 11th to the 14th week of gesta‐
tion with the CRL of 45-83 mm.
Before the screening they had all received counseling by their level one gynecologists and an
information leaflet about the ultrasound examination and the aim of the screening. In the
majority of cases the examination of early fetal morphology and other measurements was
performed transabdominally within 20 minutes. In less than 1% of the cases a transvaginal
ultrasound examination had to be carried out.
For the examinations we used 2-5 MHz and 3.7-9.3 MHz transducers GE Healthcare Volu‐
son 730 Pro, Milwaukee, USA, 4–6 MHz, 4–7 MHz, 5–9 MHz and 7–9 MHz transducers Acu‐
son S2000, Siemens Medical Solution, Mountain View CA, USA.
The measurement of fetal NT followed the criteria recommended by the Fetal Medicine
Foundation (FMF). The increased NT thickness was defined as a measurement above the
95th percentile for the normal range. Risks were calculated according to the FMF program,
following its guidelines [15,16].
The women with an increased risk for chromosomal anomalies (≥ 1:300) calculated on the
basis of maternal age, NT and fetal crown-rump length (CRL) were offered invasive testing
for fetal karyotyping. The karyotyping was performed by using chorionic villus sampling or
amniocentesis in three cytogenetic laboratories.
The fetuses with increased fetal NT and normal karyotype were followed by detailed struc‐
tural ultrasound evaluation between the 20th and the 24th week of gestation. Fetal echocar‐
diography was performed in cases in which NT exceeded 3.5 mm.
After an informed consent had been signed, pregnancy outcomes were obtained from the
participating women by written questionnaires. In cases of non-responders or uncertainty,
telephone contact with the parents was established. The length of follow-up ranged from 18
months to 5 years.
2.2. Exclusion criteria
The exclusion criteria were the loss to follow-up, the chromosomal abnormalities or no in‐
formation on karyotype in a fetal loss.
2.3. Classification of adverse outcome
Adverse pregnancy outcome was defined as fetal loss (miscarriage, intrauterine death, ter‐
mination of pregnancy), and as liveborn infant with structural abnormality, genetic disor‐
ders and/or neurodevelopmental delay diagnosed before or after delivery. Stillbirth <22
weeks of pregnancy was defined as miscarriage, and stillbirth ≥22 weeks of pregnancy or
birth of a child of at least 500 g weight without vital signs as intrauterine fetal death.
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2.4. Statistical analysis
Descriptive statistics were used to describe our sample. Means, standard deviations and
ranges are reported for continuous variables, numbers and proportions are reported for cat‐
egorical variables. Statistical analysis was performed using R statistical package, version
2.14.
3. Results
3.1. Study population
The sample represented 11,980 unselected pregnant women appointed for the first trimester
ultrasound screening examination at a single outpatient clinic between January 4, 2005 and
April 30, 2010.
Five hundred and fifty-eight fetuses had an increased fetal NT and normal karyotype
(558/11,980; 4.7%). In 46 cases (46/558; 8.2%) the outcome of the pregnancy was unknown;
therefore 512 singleton pregnancies were included in the further analysis.
The mean maternal age was 30.2 years (range from 17 to 46 years, SD=4.8). There were 421
out of 512 pregnancies (82.2%) conceived naturally and 91 (17.8%; 91/512) after in vitro fertil‐
ization. The mean NT ≥95th percentile was of 2.5 mm (range from 1.3 to 13.4 mm).
3.2. Fetal loss
The fetal loss was registered in 36 pregnancies (36/512; 7%). Twelve women (2.3%; 12/512)
had miscarriage, 19 pregnancies (3.7%; 19/512) were terminated at parental request or due to
the finding of structural abnormalities, and 1% of pregnancies (5/512) ended with intrauter‐
ine death. The outcomes with respect to the NT thickness are presented in Table 2. Table 3
provides details on all the types of fetal loss. The most common causes of termination were
hydrops fetalis, increased NT or cystic hygroma (Figure 3).
NT (mm) ≤ 3.4 3.5-4.4 4.5-5.4 5.5-6.4 ≥ 6.5 Total
Outcome
Delivery 436 34 5 1 0 476 (93%)
Miscarriage 11 0 1 0 0 12 (2.3%)
Intrauterine death 1 3 0 0 1 5 (1%)
Termination 8 2 3 2 4 19 (3.7%)
Total 456 39 9 3 5 512
Table 2. Outcome of pregnancies with respect to the NT thickness.
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Fetal loss n NT (mm)
Miscarriage (unspecified) 10 2.1/2.2/2.3/2.5/2.6/
2.9/2.9/3.0/3.0/4.6
Spontaneous abortion after amniocentesis 2 2.5/3.0
Intrauterine death (unspecified) 4 3.0/3.5/3.7/4.2
Intrauterine death/tetralogy of Fallot 1 7.8
Termination: 19
Hydrops fetalis 5 2.7/3.7/6.4/7.4/12.0
Increased NT 4 2.9/3.0/5.0/5.2
Cystic hygroma 3 12.2/13.4
Hydrocephalus 2 2.5/4.9
VSD/valve anomaly 1 3.7
Dandy-Walker malformation 1 5.6
Diaphragmatic hernia 1 3.2
Renal dysplasia 1 2.2
Neurofibromatosis type I (inherit) 1 2.1
Table 3. Fetal loss with respect to the NT thickness.
3.3. Liveborn infants with abnormalities
Four hundred and seventy-six pregnancies ended with delivery of a viable infant (93%).
Among them we found 48 newborns (9.5%; 48/476) with either single or multiple abnormali‐
ties. The clinical findings in 476 liveborn infants with respect to the NT thickness are pre‐
sented in Table 4. There were 8 cases (1.7%, 8/476) born with heart defects, other structural
abnormalities were found in 30 newborns (6.3%; 30/476). During the first year of life some
genetic syndromes or neurodevelopmental delay were recorded in 10 cases (2.1%; 10/476).
All abnormalities were found in the group of newborns with mildly enlarged NT, between
95th percentiles to 4.4 mm. Among healthy babies, there was no NT thicker than 6.4 mm.
Table 5 describes the disorders of 48 babies in more detail.
Figure 3. Hydrops fetalis
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NT (mm)≤ 3.4 3.5-4.4 4.5-5.4 5.5-6.4 ≥ 6.5 Total
Clinical findings
Healthy 393 29 5 1 0 431
Heart defect 6 2 0 0 0 8
Structural abnormalities 29 1 0 0 0 30
Genetic syndromes 5 0 0 0 0 5
Neurodevelopmental delay 4 1 0 0 0 5
Total 437 33 5 1 0 476
Table 4. Clinical findings in liveborn infants with respect to the NT thickness.
Disorder n NT (mm)
Heart defects: 8
VSD 3 2.6/3.0/3.2
VSD, ASD and aortic coarctation 1 3.9
VSD, ASD and tricuspid valve anomaly 1 4.0
Hypoplastic left ventricle 1 3.4
Isolated valve anomaly 2 3.4/2.6
Other abnormalities: 30
Hydronephrosis (isolated) 4 1.8/2.5/2.8/3.1
Hydronephrosis and ureteral stenosis 2 2.8/3.1
Vesicouretheral reflux 2 2.6/2.8
Cleft lip and/or cleft palate 4 1.5/2.1/3.1/3.1
Craniosynostosis 1 2.3
Hypoplasia of the corpus callosum 1 2.5
Hydrocephalus 1 3.2
Micrognathia 1 2.6
Hemangioma 2 1.8/1.9
Cystic adenomatoid malformation 1 2.4
Diaphragmatic hernia 1 3.2
Atresia of the duodenum 1 3.0
Unilateral renal agenesis 1 2.7
Increased Fetal Nuchal Translucency Thickness and Normal Karyotype: Prenatal and Postnatal Outcome
http://dx.doi.org/10.5772/53112
27
Disorder n NT (mm)
Cryptorchidism 2 3.2/4.4
Hypospadias 1 3.2
Polydactyly 1 2.3
Hip dysplasia 3 1.8/1.8/2.2
Talipes 1 2.9
Genetic syndromes and neurodevelopmental delay: 10
Adrenogenital syndrome 1 3.0
Lipid metabolism disorder 1 1.9
Coeliac disease 1 1.6
Polycystic kidney disease 2 2.4/2.4
Unspecific genetic syndrome and
neurodevelopmental delay
2 2.6/3.0
Neurodevelopmental delay 3 2.5/2.9/3.5
Table 5. Disorders described in forty-eight euploid infants.
3.4. Gender and preterm labor
The overall male: female ratio was 1.37:1. In the group of fetuses with NT thickness between
95th percentile to ≤ 3.4 mm the ratio was 1.27:1 and in the group with NT ≥ 3.5 mm 2.64:1.
The gender distribution of liveborn infants with respect to the abnormalities is presented in
Table 6. Male gender was predominant among healthy infants and in the group with genetic
syndromes neurodevelopmental delay.
Preterm delivery was registered in 41 cases (41/476; 8.6%). Thirty-one healthy babies (31/431;
9.5%) and 10 infants with abnormalities (10/48; 20.8%) were born preterm.
Infants Males Females
Healthy 253 175
Heart defect 1 7
Structural abnormalities 15 15
Genetic syndromes/
neurodevelopmental delay
8 2
Total 276 198
Table 6. Gender distribution of liveborn infants with respect to the abnormalities.
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4. Discussion
We evaluated the pregnancy outcome of a subgroup of 512 fetuses with increased NT thick‐
ness and normal karyotype referring to 11,980 unselected pregnancies. According to the da‐
ta of fetal loss, structural abnormalities, genetic disorders and neurodevelopmental delay,
one out of 6 fetuses had an increased risk ≥1:300 of trisomy 21 calculated on the basis of ma‐
ternal age, NT and fetal crown-rump length. The study confirms that 16.4% fetuses (84/512)
were at increased risk of adverse pregnancy outcome.
The number of studies, which examined unselected pregnancy population with clear de‐
scription of all adverse pregnancy outcomes, is limited [9]. Bilardo CM et al [14] noted that
one out of five fetuses with increased NT had an adverse pregnancy outcome. Their study
provides an overview of the selected pregnancy of 675 fetuses referred from other centers
because of an increased NT measurement.
4.1. Fetal loss
In some studies it is not clear whether the fetuses with an unknown karyotype were includ‐
ed [17,18]. This is particularly important in the cases of fetal loss. We included only fetuses
with known normal karyotypes. Karyotyping was provided in all cases of miscarriages, in‐
trauterine deaths and terminations of pregnancies using amniocentesis or tissue samples ob‐
tained during surgical evacuation of the products of conception.
The increased NT thickness augments the risk of fetal loss. The allover fetal loss in our sub‐
group of fetuses was 7% (Table 2). We share the opinion that fetal loss in studies without a
control group is very difficult to interpret [9,17-20]. The reported rates of spontaneous loss
are 0.5-3.8% and the reported rates of termination of pregnancy are 2.3-16.9%.
Fifteen women terminated their pregnancies because of the fetal abnormalities (Table 3). But
in 4 cases the pregnancy was terminated at the request of the parents because of an in‐
creased risk of trisomy 21, despite of the fact that no fetal malformation had been detected at
the ultrasound examination. Westin M et al [9] describe similar experiences.
Our study shows similar weakness compared to the related studies, namely not all fetuses
lost having undergone autopsy for ascertainment of fetal abnormalities, especially in the
group of miscarriages [9,17-20].
4.2. Liveborn infants with abnormalities
The prevalence of structural abnormalities in our subgroup of newborns with increased NT
was 8%. The percentage is higher than expected in general population (2-3%). A similar
finding can be encountered in the studies without a control group (9.5-30.3%) [9].
Heart defects were confirmed in 8 out of 38 infants with structural abnormalities. The me‐
dian NT thickness was significantly higher in fetuses with major heart defects compared to
those with normal hearts [21-24]. In 8 infants with heart defects we found NT measurement
between 3.4 and 4.4 mm. Although the measurement of NT thickness alone appears to be a
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moderately effective screening pool for the detection of heart abnormalities, its role in detec‐
tion of specific congenital heart defects seems more promising [24]. When an increased NT
is found, the fetus has to be screened for additional sonographic markers such as tricuspid
regurgitation and abnormal ductus venosus Doppler flow profile. We share the opinion that
in fetuses with an NT measurement ≥99th percentile, and/or in which tricuspid regurgita‐
tion and/or abnormal ductus venosus Doppler flow pattern is found, an earlier fetal echocar‐
diograpy is indicated [23,24].
The second most common isolated structural abnormality was hydronephrosis followed by
cleft lip and/or cleft palate (Table 5).
In 5 cases genetic syndromes were found. There were two cases of inherited polycystic kid‐
ney disease, and three “de novo” genetic syndromes. In comparison with other studies we
detected no infants with neuromuscular disorders [13,14].
As Bilardo CM et al [14] pointed out, the most unpredictable aspect of increased NT is neu‐
rodevelopmental delay, which could be manifested unexpectedly, in the postnatal period.
The reported incidence of neurodevelopmental delay in fetuses with or without recogniza‐
ble genetic syndrome varies from 0 to 13% [14,25,26]. In our study 10.4% of newborns (5 out
of 48) were diagnosed during the follow-up period of at least 18-months.
4.3. Gender and preterm labor
In our population of fetuses with increased NT thickness, male gender was predominant, es‐
pecially in the group with NT ≥ 3.5 mm. The impact of male: female ratio on the degree of
nuchal fluid accumulation has been reported with controversial results. Yaron et al [27] and
Prefumo et al [28] did not find NT to be significantly related to gender, but Lam et al [29]
and Timmerman et al [30] reported significantly larger NT in male fetuses. Also Spencer et
al [31] found NT to be 3-4% smaller in both chromosomally normal and Down syndrome
female fetuses.
5. Conclusion
Many couples enter any of the screening programs without an intricate understanding of
the potential fetal and newborn complications. While it is reasonable for the future parents
to consider normal karyotype as a “good” result, the healthcare professionals should coun‐
sel them that enlarged NT thickness is a strong marker for adverse pregnancy outcome, as‐
sociated with miscarriage, intrauterine death, heart defects, numerous other structural
abnormalities and genetic syndromes. Although the measurement of the nuchal translucen‐
cy thickness was introduced over 15 years ago, we share the opinion that a general consen‐
sus on how to counsel parents of an euploid fetus with enlarged NT has not yet been
achieved [13]. The larger studies with uniform protocols and long-term follow-up are need‐
ed to recommend the guidelines for objective parental counseling.
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